DepoMed Inc. Message Board
-
TM...scripts?
Hey tm ..do you have the scripts for this week?
-
n This week's data. New and total prescriptions for Gralise were 1,777 and
2,488 (versus 1,624 and 2,242 last week - holiday shortened week). At ~
$150/script, this translates into a ~$19.4 million annualized run rate. Total
share of gabapentin-like products increased to 0.28% from 0.27%. The
product was launched in October 2011. We view this week's Gralise data
as neutral post the bounce to a new high in total prescriptions following the
Memorial Day holiday on May 28th. Prescription trends are on track with our
target of 2,700 per week by the end of June. The 4-week moving average
increased to 46, which is slightly below our ~60 weekly target. -
WOW GREAT
-
Week of 6/8: 2,488 total
Up 11% week/week! -
This week's data. New and total prescriptions for Gralise were 1,624 and
2,242 (versus 1,675 and 2,271 last week). At ~$150/script, this translates
into a ~$17.5 million annualized run rate (company recently upped price
by ~20%). Total share of gabapentin-like products was flat at 0.27%. The
product was launched in October 2011. We view this week's Gralise data as
mostly noise given the disruption of the Memorial Day holiday on May 28th.
As a result of this noise, the 4-week moving average dipped below our ~60
weekly target. We expect a significant uptick next week. -
Includes record high refills, #596
-
This week's data. New and total prescriptions for Gralise were 1,675 and
2,271 (versus 1,662 and 2,213 last week). At ~$150/script, this translates
into a ~$17.7 million annualized run rate (company recently upped price
by ~20%). Total share of gabapentin-like products was flat at 0.27%. The
product was launched in October 2011. We view this week's Gralise data
as neutral given a modest increase over the prior week. The 4-week moving
average of 56 remains near our ~60 weekly target. -
This week's data. New and total prescriptions for Gralise were 1,662 and
2,213 (versus 1,745 and 2,303 last week). At ~$150/script, this translates
into a ~$17.3 million annualized run rate (company recently upped price
by ~20%). Total share of gabapentin-like products was flat at 0.27%. The
product was launched in October 2011. We view this week's Gralise data
as neutral given a small decline after multiple strong weeks. As a result of
this negative variance, the 4-week moving average dipped below our ~60
weekly target. -
Thanks. Another great week.
-
This week's data. New and total prescriptions for Gralise were 1,745 and
2,303 (versus 1,690 and 2,197 last week). At ~$150/script, this translates
into a ~$18.0 million annualized run rate (company recently upped price by
~20%). Total share of gabapentin-like products increased to 0.27%, versus
0.24% last week. The product was launched in October 2011. We view
this week's Gralise data as positive given a 106 prescription gain. More
importantly, the 4-week moving average for prescription gains of 79 remains
above our ~60 weekly target. -
- 3 Replies to better_yeti
-
Thanks for the graph. They need to hit over 3,000 scripts just to cover the monthly sales group cost. I have no knowledge of drug sales ramp up but the graph looks promising. doc
-
better_yeti,
Much obliged for the graph that puts into one visual the impressive gains being made for Gralise Rx's. I'd love to know which database (of PHN specialists) the sales reps are running off of, and whether they are yet moving outside of that 'comfort zone' for additional Rx's.
Translation: at what point do the reps grab the low hanging fruit and then start looking up higher in the tree (for the more difficult Rx's)?
Too bad we don't have a fly on the wall at the next sales rep annual meeting to hear their presentations of how it's going in the field. Getting such intel often yields pointers to trading DEPO. (e.g., Rx's coming more easily -- buy; Rx's getting harder to nail down -- hold). -
Thank you for sharing the impressive Gralise chart, maybe some day the stock price chart will look the same :)
- View More Messages
-